Characterization and prognostic implication of 17 chromosome abnormalities in myelodysplastic syndrome


Por: Sanchez-Castro, J, Marco-Betes, V, Gomez-Arbones, X, Arenillas, L, Valcarcel, D, Vallespi, T, Costa, D, Nomdedeu, B, Jimenez, MJ, Granada, I, Grau, J, Ardanaz, MT, de la Serna, J, Carbonell, F, Cervera, J, Sierra, A, Luno, E, Cervero, CJ, Falantes, J, Calasanz, MJ, Gonzalez-Porras, JR, Bailen, A, Amigo, ML, Sanz, G, Sole, F

Publicada: 1 jul 2013
Resumen:
The prognosis of chromosome 17 (chr17) abnormalities in patients with primary myelodysplastic syndrome (MDS) remains unclear. The revised International Prognostic Scoring System (IPSS-R) includes these abnormalities within the intermediate cytogenetic risk group. This study assessed the impact on overall survival ( OS) and risk of acute myeloid leukemia transformation (AMLt) of chr17 abnormalities in 88 patients with primary MDS. We have compared this group with 1346 patients with primary MDS and abnormal karyotype without chr17 involved. The alterations of chr17 should be considered within group of poor prognosis. The different types of alterations of chromosome 17 behave different prognosis. The study confirms the intermediate prognostic impact of the i(17q), as stated in IPSS-R. The results of the study, however, provide valuable new information on the prognostic impact of alterations of chromosome 17 in complex karyotypes. (C) 2013 Elsevier Ltd. All rights reserved.

Filiaciones:
Sanchez-Castro, J:
 Hosp Arnau Vilanova, Lleida, Spain

Marco-Betes, V:
 Hosp Arnau Vilanova, Lleida, Spain

Gomez-Arbones, X:
 Hosp Arnau Vilanova, Lleida, Spain

 Univ Lleida, Lleida, Spain

Arenillas, L:
 Hosp del Mar, Barcelona, Spain

Valcarcel, D:
 Hosp Valle De Hebron, Barcelona, Spain

Vallespi, T:
 Hosp Valle De Hebron, Barcelona, Spain

Costa, D:
 Hosp Clin Barcelona, Barcelona, Spain

Nomdedeu, B:
 Hosp Clin Barcelona, Barcelona, Spain

Jimenez, MJ:
 Hosp Badalona Germans Trias & Pujol, Barcelona, Spain

Granada, I:
 Hosp Badalona Germans Trias & Pujol, Barcelona, Spain

Grau, J:
 Hosp Badalona Germans Trias & Pujol, Barcelona, Spain

Ardanaz, MT:
 Hosp Txagorritxu, Vitoria, Spain

de la Serna, J:
 Hosp 12 Octubre, E-28041 Madrid, Spain

Carbonell, F:
 Hosp Gen Univ, Valencia, Spain

Cervera, J:
 Hosp Univ La Fe, Valencia, Spain

Sierra, A:
 Hosp Santa Creu & Sant Pau, Barcelona, Spain

Luno, E:
 Hosp Univ Cent Asturias, Oviedo, Spain

Cervero, CJ:
 Hosp Virgen de la Luz, Cuenca, Spain

Falantes, J:
 Hosp Virgen del Rocio, Seville, Spain

Calasanz, MJ:
 Univ Navarra, E-31080 Pamplona, Spain

Gonzalez-Porras, JR:
 Hosp Univ Salamanca, Salamanca, Spain

Bailen, A:
 Hosp Univ Carlos Haya, Malaga, Spain

Amigo, ML:
 Hosp Gen Univ Morales Meseguer, Murcia, Spain

Sanz, G:
 Hosp Univ La Fe, Valencia, Spain

Sole, F:
 Hosp del Mar, Barcelona, Spain

 Autonomous Univ Barcelona, Fac Life Sci, Dept Cell Biol Physiol & Immunol, Bellaterra, Spain
ISSN: 01452126





LEUKEMIA RESEARCH
Editorial
PERGAMON-ELSEVIER SCIENCE LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND, Reino Unido
Tipo de documento: Article
Volumen: 37 Número: 7
Páginas: 769-776
WOS Id: 000320583100011
ID de PubMed: 23639672
imagen Green Submitted

MÉTRICAS